Pharmacogenetics of drugs withdrawn from the market
- PMID: 22256871
- DOI: 10.2217/pgs.11.137
Pharmacogenetics of drugs withdrawn from the market
Abstract
The safety and efficacy of candidate compounds are critical factors during the development of drugs, and most drugs have been withdrawn from the market owing to severe adverse reactions. Individuals/populations with different genetic backgrounds may show significant differences in drug metabolism and efficacy, which can sometimes manifest as severe adverse drug reactions. With an emphasis on the mechanisms underlying abnormal drug effects caused by genetic mutations, pharmacogenetic studies may enhance the safety and effectiveness of drug use, provide more comprehensive delineations of the scope of usage, and change the fates of drugs withdrawn from the market.
Similar articles
-
Can pharmacogenetics help rescue drugs withdrawn from the market?Pharmacogenomics. 2006 Sep;7(6):889-908. doi: 10.2217/14622416.7.6.889. Pharmacogenomics. 2006. PMID: 16981848 Review.
-
WITHDRAWN--a resource for withdrawn and discontinued drugs.Nucleic Acids Res. 2016 Jan 4;44(D1):D1080-6. doi: 10.1093/nar/gkv1192. Epub 2015 Nov 8. Nucleic Acids Res. 2016. PMID: 26553801 Free PMC article.
-
[Pharmacogenetics and prediction of side effects of drugs].Ann Biol Clin (Paris). 2014 Jul-Aug;72(4):405-12. doi: 10.1684/abc.2014.0957. Ann Biol Clin (Paris). 2014. PMID: 25119798 Review. French.
-
Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system.Biochem Biophys Res Commun. 2010 May 21;396(1):90-4. doi: 10.1016/j.bbrc.2010.02.162. Biochem Biophys Res Commun. 2010. PMID: 20494117 Review.
-
The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.Neuropsychopharmacology. 2009 Jan;34(1):6-17. doi: 10.1038/npp.2008.153. Epub 2008 Oct 15. Neuropsychopharmacology. 2009. PMID: 18923406 Review.
Cited by
-
Organoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseases.Cell Death Dis. 2019 Feb 27;10(3):201. doi: 10.1038/s41419-019-1453-0. Cell Death Dis. 2019. PMID: 30814510 Free PMC article.
-
African Pharmacogenomics Consortium: Consolidating pharmacogenomics knowledge, capacity development and translation in Africa: Consolidating pharmacogenomics knowledge, capacity development and translation in Africa.AAS Open Res. 2019 Jun 4;2:19. doi: 10.12688/aasopenres.12965.1. eCollection 2019. AAS Open Res. 2019. PMID: 32382701 Free PMC article.
-
Facing small and biased data dilemma in drug discovery with enhanced federated learning approaches.Sci China Life Sci. 2022 Mar;65(3):529-539. doi: 10.1007/s11427-021-1946-0. Epub 2021 Jul 26. Sci China Life Sci. 2022. PMID: 34319533
-
A possible increase in liver enzymes due to amlodipine: A case report.SAGE Open Med Case Rep. 2020 Jun 24;8:2050313X20917822. doi: 10.1177/2050313X20917822. eCollection 2020. SAGE Open Med Case Rep. 2020. PMID: 32637107 Free PMC article.
-
Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease.Int J Obes (Lond). 2014 Sep;38(9):1165-71. doi: 10.1038/ijo.2014.2. Epub 2014 Jan 10. Int J Obes (Lond). 2014. PMID: 24406481 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical